Equity
€18,600 from €451,498 in 2024
Equity fell by 96% in 1 year.
GYNAN
Lifetime
7 annual accounts with figures on one time axispeak €583,094 (2024)
€421,555▼ 27.7%
peak €432,898 (2024)
€278,243▼ 35.7%
peak €451,498 (2024)
€18,600▼ 95.9%
€302,763▲ 78×
Board3 names since 2018
3 directors and 2 others
Documentsfilings and deeds
27-07-20264 days before the deadline
2025micro format
Gross margin from €583,094 to €421,555Result from €432,898 to €278,243Dividend €711,141Equity from €451,498 to €18,600Debts from €3,892 to €302,763
Key points
from the 2025 annual accountsTurnover
≈ €630,000 estimated
The micro format states no turnover.
Debts
€302,763 94% of the balance sheet
Suppliers 3%Taxes and wages 14%Other 84%
Of this, €301,248 falls due within a year.
Filings
7 annual accounts 1 late
The 2019 accounts came 118 days late. The other six were filed on time.
Starting capital
€18,600 1,860 shares
Position in the sector
5.8%
Lower solvency than 89% of companies in human health. Sector median 63.1% · 21,322 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 2,154 companies had the same profile as GYNAN has now. Each dot stands for 6 companies, two years later.
95.9%
were still trading
2.3%
stopped another way
1.7%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,154 companies, not a prediction for GYNAN. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, since 01-10-2018
Manager
Director
- 930 sharesdeed of 21-09-2018
- 930 sharesdeed of 21-09-2018
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0704772009
Registered office moved to Leuze-en-Hainaut
New registered office: Grand’Rue 18C, 7900 Leuze-en-Hainaut · Appointments: (director) and (director) · “La direction,l’organisation et la gestion de centres médicaux; Publier et diffuser des articles et ouvrages…” (deed in French) · Gazette deed
Incorporation
Founding capital of €18,600, 1,860 shares · Founders: and · Appointments: (manager) and (manager) · published on 21-09-2018 · Gazette deed
2 establishments registered
Frameries and Kortenberg
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| GYNAN Leuze-en-Hainaut | €321,363 | €421,555 | 5.8% | - |
| Dokter Hendrik Peuskens Oud-Heverlee | €336,613 | €413,470 | 5.5% | - |
| Drs. Noyez-Dom Sint-Katelijne-Waver | €342,180 | €406,890 | 0.3% | - |
| BoTho Londerzeel | €345,482 | €438,549 | 6.4% | - |
| Dr. Pieter-Jan Geerts Kortrijk | €307,634 | €410,082 | 45.7% | - |
| DR. Jense WILS Brecht | €287,941 | €414,814 | 6.5% | - |
| Dr. NGUYEN Pham Anh Hong, pneumologe Dilbeek | €313,202 | €445,994 | 10.8% | - |
These companies have the same main activity as GYNAN: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €288,000 and €345,000, founded between 2017 and 2019.
Official details
Source: KBO- Status
- Active since 19-09-2018Normal situation
- Activity
- Specialist medical practiceNACE 86220and 1 other
- Establishment units
- 2.279.676.3807080 Frameries, since 19-09-2018
- 2.279.676.4793070 Kortenberg, since 19-09-2018
- Financial year end
- 31 December
- Peppol
- Reachable since 10-03-2026
Annual accounts 2025
- €321,363▼ 29.4%
- Filing
- Filed on 27-07-2026, 4 days before the end of the filing period
Insights on GYNAN
GYNAN files the micro format. That format states no turnover. The gross margin rose from €148,383 in 2019 to €421,555 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about GYNAN
- What is the company number of GYNAN?
- The company number of GYNAN is 0704.772.009. The VAT number is the same number with BE in front: BE 0704.772.009.
- Where is GYNAN based?
- The registered office is at Grand-Rue 18, 7900 Leuze-en-Hainaut.Company details
- What does GYNAN do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of GYNAN?
- GYNAN is a private limited company (BV).
- When was GYNAN founded?
- GYNAN was founded on 19-09-2018.
- Is GYNAN still active?
- Yes, GYNAN is an active enterprise in the KBO register.
- What is the turnover of GYNAN?
- The turnover in financial year 2025 is ≈ €630,000. This figure is estimated from the gross margin of €421,555 and 31 comparable companies (NACE 86220). It probably lies between €560,000 and €880,000.Financials
- Is GYNAN profitable?
- In financial year 2025, GYNAN made a profit of €278,243.
- Where can I find the annual accounts of GYNAN?
- GYNAN filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of GYNAN due?
- GYNAN must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.